

## Supporting Information

### *O*-Cyclopropyl Hydroxylamines: Gram-Scale Synthesis and Utility as Precursors for *N*-Heterocycles

Kaitlyn Lovato<sup>[a]</sup>+, Urmibhusan Bhakta<sup>[a]</sup>+, Yi Pin Ng<sup>[b]</sup>, and László Kürti\*<sup>[a]</sup>

<sup>[a]</sup>Department of Chemistry, Rice University, BioScience Research Collaborative, 6500 Main Street, Room 380, Houston, TX, 77030 (USA)

<sup>[b]</sup> Division of Chemistry and Biological Chemistry, School of Physical & Mathematical Sciences, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798

+ These authors contributed equally to this work.

## Table of Contents

General Remarks .....	2
Preparation of <i>N</i> -enoxyphthalimides .....	2
Preparation of 2-cyclopropoxyisoindoline-1,3-diones .....	2
Characterization of 2-cyclopropoxyisoindoline-1,3-diones .....	3
Preparation and Characterization of Ring-Unsubstituted <i>O</i> -cyclopropyl Hydroxylamine Hydrochloride Salt .....	5
Preparation and Characterization of Substituted <i>O</i> -cyclopropyl Hydroxylamine.....	6
Preparation and Characterization of Unsubstituted <i>O</i> -cyclopropyl Hydroxamates.....	6
Preparation and Characterization of Substituted <i>O</i> -cyclopropyl Hydroxamate.....	8
Preparation of <i>N</i> -arylated- <i>O</i> -cyclopropyl Hydroxamates.....	9
Characterization of <i>N</i> -arylated- <i>O</i> -cyclopropyl Hydroxamates.....	9
Preparation of 2-Hydroxy-tetrahydroquinolines via [3,3] Rearrangement of <i>N</i> -arylated- <i>O</i> -cyclopropyl Hydroxamates .....	14
Characterization of 2-hydroxy-tetrahydroquinolines .....	15
Preparation of Derivatized 2-hydroxy-tetrahydroquinoline Products.....	21
References .....	24
NMR Spectra of Reported Compounds .....	25


## General Remarks

All starting material syntheses were performed in oven-dried 50 mL or 100 mL round-bottomed flasks. Commercially available solvents and reagents were used without further purification. All arylation reactions were carried out in oven-dried 8 mL scintillation vials, while rearrangement reactions were carried out in oven-dried 20 mL scintillation vials. All reactions were monitored by thin-layer chromatography (TLC) with E. Merck silica gel 60 F254 pre-coated plates (0.25 mm). Flash chromatography was carried out using a Biotage Isolera One system with 10g KP-Sil cartridges utilizing ethyl acetate (EA) and hexane (hex) as eluents.  $^1\text{H}$  and  $^{13}\text{C}$  nuclear magnetic resonance (NMR) spectra were obtained using a Bruker DRX-600 NMR spectrometer. Chemical shifts are documented in parts per million ( $\delta$ , ppm).  $^1\text{H}$  NMR spectra are referenced to 7.26 ( $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR spectra are referenced to 77.16 ( $\text{CDCl}_3$ ). The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, p = pentet, br s = broad singlet, dd = doublet of doublets, ddd = doublet of doublet of doublets, dddd = doublet of doublet of doublet of doublets, dt = doublet of triplets, td = triplet of doublets, dtd = doublet of triplet of doublets, tt = triplet of triplets, dp = doublet of pentets, ddt = doublet of doublet of triplets, dtdd = doublet of triplet of doublet of doublets, tddd = triplet of doublet of doublet of doublets, dqt = doublet of quartet of triplets, qd = quartet of doublets, dtt = doublet of triplet of triplets, qt = quartet of triplets, dq = doublet of quartets, tq = triplet of quartets. High Resolution Mass Spectrometry was performed on an Agilent 1290/6230 LCMS-TOF under electrospray ionization (ESI) conditions in both positive and negative mode. Melting points were recorded on a Mettler Toledo MP50 melting point system.

## Preparation of *N*-enoxyphthalimides


The preparation of the *N*-enoxyphthalimides was carried out following literature reported protocols. *N*-enoxyphthalimide **15a** was synthesized following protocol A<sup>[1]</sup> and the *N*-enoxyphthalimides (**15b-15g**) (i.e. those used to synthesize 2-cyclopropoxyisoindolin-1,3-diones (**16b-16g**) were synthesized following the copper promoted protocol B<sup>[2]</sup>. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of the obtained *N*-enoxyphthalimides were consistent with those reported in the literature.<sup>[1-3]</sup>

### 2-(vinylloxy)isoindoline-1,3-dione (**15a**)



The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra for 2-(vinylloxy)isoindoline-1,3-dione were consistent with those reported in the literature.<sup>[1]</sup>

## Preparation of 2-cyclopropoxyisoindoline-1,3-diones




Neat diethylzinc (20.5 mL, 200 mmol, 2.0 equiv) was added to 250 mL of dry DCM under inert atmosphere in a glove box. The diethylzinc solution was removed from the glove box and kept under inert gas. A

solution of trifluoroacetic acid (15.3 mL, 200 mmol, 2.0 equiv) in DCM (125 mL) was slowly added to the diethylzinc solution at 0 °C and stirred until gas evolution ceased. After stirring at 0 °C for about 20 minutes, a solution of diiodomethane (16.13 mL, 200 mmol, 2.0 equiv) in DCM (125 mL) was added. The mixture was stirred for an additional 20 minutes. Upon further stirring, a solution of *N*-enoxyphthalimide **15a** (22.7 g, 120 mmol, 1.0 equiv) in DCM (100 mL) was added. Then the reaction was removed from the ice bath, allowed to warm to rt and stirred for 2 h or until the reaction was complete by TLC analysis. Once the starting material was consumed, the reaction mixture was decanted into a separatory funnel and carefully quenched with 0.1 N HCl (500 mL). The organic layer was separated and washed with saturated NaHCO<sub>3</sub>, and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated.<sup>[4]</sup> The crude mixture was purified via flash chromatography (30% EA in hexanes) to give 2-cyclopropoxyisoindoline-1,3-dione **16a** as a white solid. The same procedure was used to synthesize **16b-16g** from the corresponding *N*-enoxyphthalimides.

## Characterization of 2-cyclopropoxyisoindoline-1,3-diones

### 2-cyclopropoxyisoindoline-1,3-dione (**16a**)




<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.85 (dd, *J* = 5.4, 3.1 Hz, 2H), 7.75 (dd, *J* = 5.5, 3.1 Hz, 2H), 4.40 (tt, *J* = 6.1, 2.7 Hz, 1H), 1.18 – 1.14 (m, 2H), 0.70 – 0.66 (m, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 163.70 (2C), 134.61 (2C), 129.12 (2C), 123.71 (2C), 61.57, 6.90 (2C).

**Yield:** 2.16 g, 94%. White solid (m.p. 76.0 °C).

**HRMS (ESI):** *m/z* calcd for [C<sub>11</sub>H<sub>9</sub>NO<sub>3</sub>]<sup>+</sup> ([M+H]<sup>+</sup>): 204.0655, found 204.0655

### 2-((1*R*,2*R*)-2-butylcyclopropoxy)isoindoline-1,3-dione (**16b**)




<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.84 (td, *J* = 5.2, 3.5 Hz, 2H), 7.75 (dd, *J* = 5.5, 3.1 Hz, 2H), 4.11 (dt, *J* = 6.5, 2.4 Hz, 1H), 1.50 (dtd, *J* = 12.9, 9.3, 8.3, 6.0 Hz, 1H), 1.32 – 1.23 (m, 5H), 1.17 (dq, *J* = 17.6, 6.9 Hz, 2H), 0.81 (t, *J* = 7.0 Hz, 3H), 0.49 (q, *J* = 6.4 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 163.68 (2C), 134.57 (2C), 129.10 (2C), 123.66 (2C), 67.20, 30.98, 30.62, 22.34, 20.41, 14.05, 13.67.

**Yield:** 1.23 g, 95%. Tan solid (m.p. 79.9 °C).

**HRMS (ESI):** *m/z* calcd for [C<sub>15</sub>H<sub>17</sub>NO<sub>3</sub>K]<sup>+</sup> ([M+K]<sup>+</sup>): 298.0840, found 298.0858

### 2-((1*R*,2*S*)-2-cyclohexylcyclopropoxy)isoindoline-1,3-dione (16c)




<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.84 (dd, *J* = 5.4, 3.1 Hz, 2H), 7.75 (dd, *J* = 5.5, 3.1 Hz, 2H), 4.16 (dt, *J* = 6.3, 2.5 Hz, 1H), 1.69 – 1.57 (m, 5H), 1.37 (dddd, *J* = 11.3, 9.2, 6.7, 2.3 Hz, 1H), 1.22 (ddd, *J* = 10.6, 6.1, 2.6 Hz, 1H), 1.16 – 1.08 (m, 3H), 1.01 (dddd, *J* = 15.5, 11.6, 7.5, 4.3 Hz, 2H), 0.62 – 0.52 (m, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 163.68 (2C), 134.58 (2C), 129.09 (2C), 123.69 (2C), 66.24, 39.40, 32.49, 31.83, 26.92, 26.41, 26.12, 26.08, 12.47.

**Yield:** 262.5 mg, 92%. White solid (m.p. 109.8 °C).

**HRMS (ESI):** *m/z* calcd for [C<sub>17</sub>H<sub>20</sub>NO<sub>3</sub>]<sup>+</sup> ([M+H]<sup>+</sup>): 286.1438, found 286.1441

### 2-(1-methylcyclopropoxy)isoindoline-1,3-dione (16d)




<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.83 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.75 (dd, *J* = 5.5, 3.1 Hz, 2H), 1.59 (s, 3H), 1.43 – 1.40 (m, 2H), 0.60 – 0.57 (m, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 164.73 (2C), 134.60 (2C), 129.29 (2C), 123.66 (2C), 67.80, 21.05, 14.13 (2C).

**Yield:** 206.3 mg, 95%. White solid (m.p. 93.4 °C).

**HRMS (ESI):** *m/z* calcd for [C<sub>12</sub>H<sub>12</sub>NO<sub>3</sub>]<sup>+</sup> ([M+H]<sup>+</sup>): 218.0812, found 218.0795

### 2-(1-phenylcyclopropoxy)isoindoline-1,3-dione (16e)




<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.70 (ddt, *J* = 19.1, 5.5, 3.2 Hz, 4H), 7.57 (dd, *J* = 6.6, 3.0 Hz, 2H), 7.32 (p, *J* = 3.5 Hz, 3H), 1.85 – 1.80 (m, 2H), 1.14 – 1.10 (m, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 163.90 (2C), 137.30, 134.43 (4C), 130.27 (2C), 129.05, 128.24 (2C), 123.52 (2C), 72.57, 13.55 (2C).

**Yield:** 252.0 mg, 90%. White solid.

### 2-((1*R*,2*R*)-1,2-dimethylcyclopropoxy)isoindoline-1,3-dione (16f)




<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.84 (dd, *J* = 5.4, 3.1 Hz, 2H), 7.75 (dd, *J* = 5.5, 3.1 Hz, 2H), 1.70 (dp, *J* = 10.5, 6.5 Hz, 1H), 1.55 (s, 3H), 1.55 – 1.52 (m, 1H), 1.04 (d, *J* = 6.4 Hz, 3H), 0.19 (dd, *J* = 7.0, 5.6 Hz, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 164.90 (2C), 134.59 (2C), 129.37 (2C), 123.67 (2C), 71.26, 20.72, 19.04, 16.55, 13.93.

**Yield:** 208.1 mg, 90%. White solid (m.p. 111.0 °C).

**HRMS (ESI):** *m/z* calcd for [C<sub>13</sub>H<sub>13</sub>NO<sub>3</sub>]<sup>+</sup> ([M+H]<sup>+</sup>): 254.0788, found 254.0774

## 2-(bicyclo[4.1.0]heptan-1-yloxy)isoindoline-1,3-dione (**16g**)




$^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.83 (dd,  $J = 5.4, 3.1$  Hz, 2H), 7.74 (dd,  $J = 5.5, 3.0$  Hz, 2H), 2.39 (dddd,  $J = 13.4, 9.5, 5.9, 1.6$  Hz, 1H), 2.17 (dt,  $J = 13.4, 5.4$  Hz, 1H), 2.03 – 1.95 (m, 1H), 1.85 – 1.73 (m, 1H), 1.56 – 1.47 (m, 2H), 1.42 (dddd,  $J = 14.4, 8.1, 5.9, 1.8$  Hz, 1H), 1.24 (dtdd,  $J = 25.6, 13.2, 6.5, 2.9$  Hz, 2H), 1.08 (tddd,  $J = 12.8, 9.7, 6.5, 3.9$  Hz, 1H), 0.46 (t,  $J = 6.2$  Hz, 1H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  164.91 (2C), 134.57 (2C), 129.31 (2C), 123.64 (2C), 70.70, 28.02, 24.16, 21.60, 21.27, 19.27, 18.46.

**Yield:** 190.3mg, 74%. Yellow solid (m.p. 75.3 °C).


**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{15}\text{H}_{16}\text{NO}_3]^+$  ( $[\text{M}+\text{H}]^+$ ): 258.1125, found 258.1110

## Preparation and Characterization of Ring-unsubstituted *O*-cyclopropyl Hydroxylamine Hydrochloride Salt



Hydrazine hydrate (50-60 %, 7.5 ml, 118 mmol, 2.8 equiv) was added dropwise (over 3 minutes) to a solution of 2-cyclopropoxyisoindoline-1,3-dione **16a** (8.5 g, 42 mmol, 1.0 equiv) in diethyl ether (167 ml, 0.25 M) at 0 °C. The reaction mixture was allowed to warm to rt and stirred for 30 minutes. The turbid mixture turned clear with a white precipitate. The precipitated diazine byproduct was filtered and washed with diethyl ether (60 ml). The combined ether filtrate was re-cooled to 0 °C and 2M HCl in ether (31.5 ml, 63 mmol, 1.5 equiv) was added over 3 minutes. The flask was stirred at 0 °C for an additional 30 minutes. The mixture was filtered, and the white solid was collected and dried to give the desired *O*-cyclopropyl hydroxylamine hydrochloride salt **17a** as a white solid.

## *O*-cyclopropylhydroxylamine hydrochloride salt (**17a**)




$^1\text{H NMR}$  (600 MHz,  $\text{DMSO-}d_6$ )  $\delta$  11.21 (br s, 2H), 4.13 (tt,  $J = 5.8, 2.6$  Hz, 1H), 0.88 (q,  $J = 4.6, 3.5$  Hz, 2H), 0.67 (qd,  $J = 6.4, 1.4$  Hz, 2H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{DMSO-}d_6$ )  $\delta$  57.26, 6.62 (2C).

**Yield:** 8.55 g, 73%. White solid (m.p. 57.1 °C).


**HRMS (CI):**  $m/z$  calcd for  $[\text{C}_3\text{H}_8\text{NO}]^+$  ( $[\text{M}]^+$ ): 74.0600, found 74.0607

## Preparation and Characterization of Ring-substituted *O*-cyclopropyl Hydroxylamine



Hydrazine hydrate (50-60 %, 0.60 ml, 9.5 mmol, 2.8 equiv) was added dropwise (over 2 minutes) to a solution of 2-((1*R*,2*R*)-2-butylcyclopropoxy)isoindoline-1,3-dione **16b** (877 mg, 3.38 mmol, 1.0 equiv) in diethyl ether (16.9 ml, 0.2 M) at  $0\text{ }^\circ\text{C}$ . The reaction mixture was removed from the ice bath and allowed to warm to rt. After stirring for 30 minutes, the turbid mixture turned clear with a white precipitate. The precipitated diazine byproduct was filtered and washed with diethyl ether (4.8 ml). The combined filtrate was concentrated and yielded the desired *O*-((1*R*,2*R*)-2-butylcyclopropyl)hydroxylamine product **17b** as a colorless oil.

### *O*-((1*R*,2*R*)-2-butylcyclopropyl)hydroxylamine (**17b**)




$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  64.42, 31.29, 31.18, 22.53, 19.66, 14.18, 12.90.

**Yield:** 792 mg, 78%. Colorless oil.

**HRMS (CI):**  $m/z$  calcd for  $[\text{C}_7\text{H}_{16}\text{NO}]^+$  ( $[\text{M}+\text{H}]^+$ ): 130.1226, found 130.1234


## Preparation and Characterization of Unsubstituted *O*-cyclopropyl Hydroxamates



To a suspension of *O*-cyclopropyl hydroxylamine hydrochloride salt **17a** (3.87 g, 35.3 mmol, 1.0 equiv) in  $\text{H}_2\text{O}/\text{THF}$  (3:4, 140 mL, 0.25 M) was slowly added  $\text{NaHCO}_3$  (2.52g, 30 mmol, 0.85 equiv) at rt. Once the solution became clear, DMAP (43 mg, 0.353 mmol, 1 mol %) was added.  $\text{Boc}_2\text{O}$  (8.08 g, 37.07 mmol, 1.05 equiv) was dissolved in THF (24 mL) and added dropwise to the solution via syringe. The reaction mixture was left stirring at rt overnight. Upon completion via TLC, the reaction mixture was concentrated and re-dissolved in EA (140 mL). The organic layer was separated and washed with  $\text{NaHSO}_4$ ,  $\text{H}_2\text{O}$  and brine. The organic layer was then dried over  $\text{MgSO}_4$ , filtered and concentrated in vacuo. The crude residue

was purified using flash chromatography (30% EA in hexanes) on a Biotage Isolera system to give the corresponding *tert*-butyl cyclopropoxycarbamate **18a** as a colorless oil.


***tert*-butyl cyclopropoxycarbamate (18a)**

  $^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.35 (br s, 1H), 3.88 (tt,  $J = 5.9, 2.7$  Hz, 1H), 1.45 (s, 9H), 0.77 (d,  $J = 7.5$  Hz, 2H), 0.56 – 0.47 (m, 2H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  156.8, 81.6, 58.7, 28.1 (3C), 5.7 (2C).


**Yield:** 4.57 g, 75%. Colorless oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_8\text{H}_{15}\text{NO}_3]^+$  ( $[\text{M}+\text{Na}]^+$ ): 196.0944; found 196.0917



A suspension of *O*-cyclopropyl hydroxylamine hydrochloride salt **17a** (1.1 g, 10 mmol) in  $\text{H}_2\text{O}/\text{THF}$  (3:4, 40 mL, 0.25 M) was cooled to 0 °C and stirred for 5 min. Then,  $\text{NaHCO}_3$  (2.52 g, 30 mmol, 3.0 equiv) followed by the corresponding chloroformate (i.e. benzyl chloroformate, methyl chloroformate, ethyl chloroformate, 15 mmol, 1.5 equiv) were added at 0 °C. The reaction mixture was removed from the ice bath and allowed to warm to rt. Reaction progress was monitored via TLC. Once the reaction was complete, the mixture was diluted with EA (20 mL). The layers were separated, and the organic layer was washed twice with  $\text{H}_2\text{O}$ , followed by  $\text{NH}_4\text{Cl}$ , and brine. The solution was dried with  $\text{Na}_2\text{SO}_4$ , filtered and concentrated in vacuo. The crude residue was purified using flash chromatography (30% EA in hexanes) on a Biotage Isolera system to give the corresponding *N*-protected-*O*-cyclopropyl hydroxamates (**18b-18d**).

**benzyl cyclopropoxycarbamate (18b)**


  $^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.41 – 7.35 (m, 6H), 5.19 (s, 2H), 3.96 (tt,  $J = 5.9, 2.8$  Hz, 1H), 0.85 – 0.80 (m, 2H), 0.60 – 0.55 (m, 2H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  157.51, 135.72, 128.75 (2C), 128.60, 128.48 (2C), 67.76, 59.37, 6.03 (2C).

**Yield:** 497 mg, 78%. White solid (m.p. 56.3 °C).

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{11}\text{H}_{13}\text{NO}_3\text{Na}]^+$  ( $[\text{M}+\text{Na}]^+$ ): 230.0788, found 230.0783


### methyl cyclopropoxycarbamate (18c)



**Yield:** 233.6 mg, 59%. Colorless liquid.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_5\text{H}_9\text{NO}_3\text{K}]^+$  ( $[\text{M}+\text{K}]^+$ ): 170.0214, found 170.0113


### ethyl cyclopropoxycarbamate (18d)



**Yield:** 275 mg, 52%. Colorless liquid.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_6\text{H}_{11}\text{NO}_3\text{Na}]^+$  ( $[\text{M}+\text{Na}]^+$ ): 168.0631, found 168.0612


## Preparation and Characterization of Substituted *O*-cyclopropyl Hydroxamate



To a solution of *O*-((1*R*,2*R*)-2-butylcyclopropyl)hydroxylamine **17b** (370 mg, 2.87 mmol, 1.0 equiv) in  $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$  (4:3, 11.5 mL, 0.25 M) was slowly added  $\text{NaHCO}_3$  (253 mg, 3.0 mmol, 1.05 equiv) at rt. Once the solution became clear, DMAP (3.5 mg, 28.7  $\mu\text{mol}$ , 1 mol %) was added.  $\text{Boc}_2\text{O}$  (657 mg, 3.0 mmol, 1.05 equiv) was dissolved in THF (2 mL) and added dropwise to the solution via syringe. The reaction mixture was left stirring at rt overnight. Upon completion via TLC, the reaction mixture was concentrated and re-dissolved in EA (11.5 mL). The organic layer was separated and washed with  $\text{NaHSO}_4$ ,  $\text{H}_2\text{O}$  and brine. The organic layer was then dried over  $\text{MgSO}_4$ , filtered and concentrated in vacuo. The crude residue was purified using flash chromatography (30% EA in hexanes) on a Biotage Isolera system to give the corresponding *tert*-butyl ((2*R*)-2-butylcyclopropoxy)carbamate **18e** as a colorless oil.



### *tert*-butyl ((2*R*)-2-butylcyclopropoxy)carbamate (**18e**)


  $^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.15 (br s, 1H), 3.62 (dt,  $J = 6.5, 2.1$  Hz, 1H), 1.48 (s, 9H), 1.38 – 1.28 (m, 4H), 1.16 (dq,  $J = 11.7, 5.9, 3.8$  Hz, 3H), 0.91 (ddt,  $J = 8.6, 6.0, 2.7$  Hz, 1H), 0.87 (t,  $J = 7.0$  Hz, 3H), 0.37 (q,  $J = 5.9$  Hz, 1H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  156.94, 81.82, 64.90, 31.17, 30.94, 28.33 (3C), 22.43, 19.53, 14.15, 12.87.

**Yield:** 132.0 mg, 72%. Colorless oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{12}\text{H}_{23}\text{NO}_3\text{Na}]^+$  ( $[\text{M}+\text{Na}]^+$ ): 252.1570, found 252.1559


### Preparation of *N*-arylated-*O*-cyclopropyl Hydroxamates



In an oven-dried 8 mL vial, *O*-cyclopropyl hydroxamate (0.3 mmol, 1.0 equiv) and cesium carbonate (196mg, 0.6 mmol, 2.0 equiv) were suspended in dry toluene (1.5 mL, 0.1 M). The desired diaryliodonium salt (0.45 mmol, 1.5 equiv) was added at room temperature in one portion. The mixture was stirred for 5-24 hours at room temperature, until TLC indicated complete consumption of the *O*-cyclopropyl hydroxamate starting material. Upon reaction completion, the mixture was filtered through celite. The celite was washed four times with ethyl acetate (5 ml each), the filtrate was collected, and the solvent was removed in vacuo. The crude product was purified using flash chromatography (10% EA in hexanes) on a Biotage Isolera system to give the desired *N*-arylated-*O*-cyclopropyl hydroxamate products.

### Characterization of *N*-arylated-*O*-cyclopropyl Hydroxamates

#### *tert*-butyl cyclopropoxy(phenyl)carbamate (**19a**)


  $^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.41 (d,  $J = 7.3$  Hz, 2H), 7.33 (d,  $J = 15.8$  Hz, 2H), 7.16 (t,  $J = 7.4$  Hz, 1H), 4.00 (tt,  $J = 6.1, 2.8$  Hz, 1H), 1.53 (s, 9H), 0.87 (dp,  $J = 6.2, 3.2$  Hz, 2H), 0.53 (qd,  $J = 6.3, 1.3$  Hz, 2H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  154.08, 141.53, 128.49 (2C), 125.63, 122.75 (2C), 82.23, 58.04, 28.33 (3C), 5.68 (2C).

**Yield:** 510 mg, 63%. Yellow oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{14}\text{H}_{19}\text{NO}_3\text{Na}]^+$  ( $[\text{M}+\text{Na}]^+$ ): 272.1257, found 272.1268

**methyl cyclopropoxy(phenyl)carbamate (19b)**




$^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.41 (d,  $J = 7.3$  Hz, 2H), 7.36 (t,  $J = 7.9$  Hz, 2H), 7.22 (t,  $J = 7.3$  Hz, 1H), 4.02 (tt,  $J = 6.0, 2.8$  Hz, 1H), 3.82 (s, 3H), 0.85 (dt,  $J = 4.8, 3.2, 2.1$  Hz, 2H), 0.56 – 0.52 (m, 2H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  155.68, 141.02, 128.77 (2C), 126.41, 123.31 (2C), 58.38, 53.55, 5.71 (2C).

**Yield:** 241 mg, 55%. Yellow oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{11}\text{H}_{13}\text{NO}_3 + \text{H}]^+ [-\text{H}_2\text{O}](\text{[M]})$ : 190.0868, found 190.0857

**ethyl cyclopropoxy(phenyl)carbamate (19c)**




$^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.42 (d,  $J = 8.9$  Hz, 2H), 7.35 (t,  $J = 8.0$  Hz, 2H), 7.20 (t,  $J = 7.2$  Hz, 1H), 4.28 (q,  $J = 7.1$  Hz, 2H), 4.02 (dt,  $J = 6.3, 3.3$  Hz, 1H), 1.33 (t,  $J = 7.1$  Hz, 3H), 0.88 – 0.84 (m, 2H), 0.56 – 0.52 (m, 2H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  155.21, 141.16, 128.73 (2C), 126.16, 123.07 (2C), 62.70, 58.35, 14.65, 5.74 (2C).

**Yield:** 254 mg, 57%. Yellow oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{12}\text{H}_{15}\text{NO}_3\text{Na}]^+ (\text{[M+Na]}^+)$ : 244.0944, found 244.0926

**benzyl cyclopropoxy(phenyl)carbamate (19d)**




$^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.44 – 7.41 (m, 1H), 7.39 – 7.31 (m, 4H), 7.23 – 7.19 (m, 1H), 5.26 (s, 1H), 4.02 (tt,  $J = 6.0, 2.9$  Hz, 1H), 0.86 – 0.82 (m, 1H), 0.52 (ddd,  $J = 5.4, 4.1, 2.7$  Hz, 1H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  155.03, 140.96, 136.00, 128.75 (3C), 128.66 (2C), 128.35, 128.17 (2C), 126.34, 123.21, 68.11, 58.40, 5.76 (2C).

**Yield:** 35 mg, 62%. Colorless oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{17}\text{H}_{17}\text{NO}_3\text{Na}]^+ (\text{[M+Na]}^+)$ : 306.1101, found 306.1105

**tert-butyl (4-bromophenyl)(cyclopropoxy)carbamate (19e)**




$^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.44 (d,  $J = 8.9$  Hz, 2H), 7.29 (d,  $J = 8.9$  Hz, 2H), 3.98 (tq,  $J = 6.8, 4.0, 3.4$  Hz, 1H), 1.52 (s, 9H), 0.91 – 0.83 (m, 2H), 0.58 – 0.51 (m, 2H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  153.6, 140.6, 131.4, 123.8, 118.5, 82.7, 58.2, 28.2, 5.6.

**Yield:** 13 mg, 12%. Colorless liquid.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{14}\text{H}_{18}\text{BrNO}_3\text{Na}]^+ (\text{[M+Na]}^+)$ : 350.0362; found 350.0381

***tert*-butyl (4-chlorophenyl)(cyclopropoxy)carbamate (19f)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)** δ 7.36 – 7.33 (m, 2H), 7.31 – 7.28 (m, 2H), 4.00 – 3.96 (m, 1H), 1.52 (s, 9H), 0.85 (th, *J* = 2.8, 1.5 Hz, 2H), 0.54 (dq, *J* = 6.1, 1.2 Hz, 2H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)** δ 153.86, 140.24, 130.87, 128.63 (2C), 123.74 (2C), 82.75, 58.31, 28.36 (3C), 5.76 (2C).

**Yield:** 18 mg, 21%. Yellow oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>14</sub>H<sub>18</sub>ClNO<sub>3</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 306.0867, found 306.0856

**benzyl (4-chlorophenyl)(cyclopropoxy)carbamate (19g)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)** δ 7.40 – 7.35 (m, 7H), 7.33 – 7.30 (m, 2H), 5.26 (s, 2H), 4.01 (dt, *J* = 6.2, 3.2 Hz, 1H), 0.83 (tt, *J* = 5.2, 3.1 Hz, 2H), 0.55 – 0.50 (m, 2H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)** δ 201.79, 154.80, 139.61, 135.77, 131.56, 128.85 (2C), 128.73 (2C), 128.50, 128.27 (2C), 124.07, 68.36, 58.64, 5.80 (2C).

**Yield:** 35.2 mg, 38%. Yellow oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>17</sub>H<sub>16</sub>ClNO<sub>3</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 340.0711, found 340.0697

***tert*-butyl (4-cyanophenyl)(cyclopropoxy)carbamate (19h)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)**: δ 7.61 (d, *J* = 8.9 Hz, 2H), 7.57 (d, *J* = 8.9 Hz, 2H), 4.02 (tt, *J* = 6.0, 2.8 Hz, 1H), 1.56 (s, 9H), 0.94 – 0.89 (m, 2H), 0.61 – 0.56 (m, 2H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)**: δ 152.8, 145.2, 132.5, 120.5, 118.8, 107.5, 83.6, 58.7, 28.2, 5.7.

**Yield:** 23 mg, 27%. Colorless oil.

***tert*-butyl cyclopropoxy(4-(trifluoromethyl)phenyl)carbamate (19i)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)**: δ 7.57 (q, *J* = 8.9 Hz, 4H), 4.02 (s, 1H), 1.55 (s, 9H), 0.90 (s, 2H), 0.57 (q, *J* = 6.0 Hz, 2H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)**: δ 153.3, 144.5, 126.6 (q, *J* = 32.7 Hz), 125.58 (q, *J* = 3.7 Hz), 124.4 (q, *J* = 271.6 Hz), 120.9, 83.1, 58.5, 28.2, 5.7.

**Yield:** 39 mg, 41%. Colorless liquid.

**HRMS (ESI):** *m/z* calcd for [C<sub>15</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>3</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 340.1131; found 340.1150

**methyl cyclopropoxy(4-(trifluoromethyl)phenyl)carbamate (19j)**




$^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.59 (q,  $J = 9.1$  Hz, 4H), 4.05 (tt,  $J = 6.1, 2.8$  Hz, 1H), 3.87 (s, 3H), 0.88 (qt,  $J = 3.9, 2.2$  Hz, 2H), 0.57 (dq,  $J = 6.2, 1.2$  Hz, 2H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  155.06, 144.08, 127.34 (q,  $J = 32.8$  Hz), 125.91 (2C, q,  $J = 3.8$  Hz), 125.04 (q,  $J = 286.9$  Hz), 121.31 (2C), 58.99, 53.83, 5.79 (2C).

**Yield:** 165.6 mg, 60%. Yellow oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{12}\text{H}_{13}\text{F}_3\text{NO}_3]^+$  ( $[\text{M}+\text{H}]^+$ ): 276.0842, found 276.0859

**ethyl cyclopropoxy(4-(trifluoromethyl)phenyl)carbamate (19k)**




$^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.63 – 7.55 (m, 4H), 4.32 (q,  $J = 7.1$  Hz, 2H), 4.05 (tt,  $J = 6.0, 2.8$  Hz, 1H), 1.37 (t,  $J = 7.1$  Hz, 3H), 0.90 (q,  $J = 5.8, 5.2$  Hz, 2H), 0.60 – 0.54 (m, 2H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  154.57, 144.19, 127.15 (q,  $J = 32.7$  Hz), 125.87 (2C, q,  $J = 3.7$  Hz), 124.18 (q,  $J = 271.8$  Hz), 121.14 (2C), 63.16, 58.92, 14.56, 5.82 (2C).

**Yield:** 39.0 mg, 67%. Yellow oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{13}\text{H}_{15}\text{F}_3\text{NO}_3]^+$  ( $[\text{M}+\text{H}]^+$ ): 290.0999, found 290.1002

**benzyl cyclopropoxy(4-(trifluoromethyl)phenyl)carbamate (19l)**




$^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.61 (s, 4H), 7.45 – 7.34 (m, 5H), 5.30 (s, 2H), 4.06 (tt,  $J = 6.1, 2.8$  Hz, 1H), 0.92 – 0.86 (m, 2H), 0.56 (h,  $J = 5.2$  Hz, 2H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  154.33, 143.93, 135.45, 128.68 (2C), 128.53, 128.29 (2C), 127.18 (q,  $J = 32.7$  Hz), 125.79 (2C, q,  $J = 3.7$  Hz), 124.04 (q,  $J = 271.8$  Hz), 121.14 (2C), 68.50, 58.90, 5.74 (2C).

**Yield:** 69.2 mg, 66%. Colorless oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{18}\text{H}_{16}\text{F}_3\text{NO}_3\text{Na}]^+$  ( $[\text{M}+\text{Na}]^+$ ): 374.0974, found 374.0985

***tert*-butyl (3,5-bis(trifluoromethyl)phenyl)(cyclopropoxy)carbamate (19m)**




$^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.93 (s, 2H), 7.62 (s, 1H), 4.03 (tt,  $J = 6.0, 2.8$  Hz, 1H), 1.56 (s, 9H), 0.99 – 0.88 (m, 2H), 0.61 (q,  $J = 6.7, 2\text{H}$ ).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  152.8, 143.0, 131.8 (q,  $J = 33.5$  Hz), 123.2 (q,  $J = 272.7$  Hz), 120.6 (q,  $J = 3.8$  Hz), 117.9 (pent,  $J = 3.8$  Hz), 83.9, 58.9, 28.1, 5.8.

**Yield:** 72 mg, 62%. Colorless oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{16}\text{H}_{17}\text{F}_6\text{NO}_3\text{Na}]^+$  ( $[\text{M}+\text{Na}]^+$ ): 408.1005; found 408.1018

**tert-butyl (3-acetylphenyl)(cyclopropoxy)carbamate (19n)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):** δ 7.93 (d, *J* = 8.8 Hz, 2H), 7.53 (d, *J* = 8.8 Hz, 2H), 4.03 (tt, *J* = 6.0, 2.8 Hz, 1H), 2.57 (s, 3H), 1.55 (s, 9H), 0.96 – 0.87 (m, 2H), 0.56 (tt, *J* = 6.7, 3.2 Hz, 2H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):** δ 196.9, 152.9, 145.4, 133.2, 128.8, 120.2, 83.0, 58.5, 28.1, 26.4, 5.6.

**Yield:** 41 mg, 47%. Colorless oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>16</sub>H<sub>21</sub>NO<sub>4</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 314.1363; found 314.1379

**tert-butyl cyclopropoxy(4-(trifluoromethyl)phenyl)carbamate (19o)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):** δ 8.00 (d, *J* = 8.7 Hz, 2H), 7.51 (d, *J* = 8.7 Hz, 2H), 4.02 (tt, *J* = 5.9, 2.7 Hz, 1H), 3.90 (s, 3H), 1.55 (s, 9H), 0.91 (d, *J* = 7.6 Hz, 2H), 0.55 (q, *J* = 6.1 Hz, 2H);

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):** δ 166.6, 153.1, 145.4, 130.0, 126.1, 120.3, 82.9, 58.5, 52.0, 28.2, 5.6.

**Yield:** 42 mg, 45%. Colorless oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>16</sub>H<sub>21</sub>NO<sub>5</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 330.1312; found 330.1333

**methyl 4-(cyclopropoxy(methoxycarbonyl)amino)benzoate (19p)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)** δ 8.01 (dd, *J* = 8.8, 2.9 Hz, 2H), 7.52 (dd, *J* = 8.8, 2.8 Hz, 2H), 4.04 (tq, *J* = 6.1, 3.0 Hz, 1H), 3.89 (d, *J* = 3.1 Hz, 3H), 3.85 (d, *J* = 3.0 Hz, 3H), 0.90 – 0.85 (m, 2H), 0.57 – 0.52 (m, 2H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)** δ 166.57, 154.86, 144.94, 130.28 (2C), 126.79, 120.60 (2C), 58.94, 53.75, 52.16, 5.74 (2C).

**Yield:** 46.3 mg, 56%. Yellow oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>13</sub>H<sub>15</sub>NO<sub>5</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 288.0842, found 288.0838

**tert-butyl cyclopropoxy(4-nitrophenyl)carbamate (19q)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)** δ 8.20 (d, *J* = 9.2 Hz, 2H), 7.63 (d, *J* = 9.2 Hz, 2H), 4.08 – 4.03 (m, 1H), 1.58 (s, 9H), 0.94 (tq, *J* = 5.4, 3.2 Hz, 2H), 0.63 – 0.58 (m, 2H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)** δ 152.77, 147.06, 143.95, 124.41 (2C), 120.03 (2C), 83.99, 59.06, 28.32 (3C), 5.92 (2C).

**Yield:** 195.0 mg, 66%. Yellow solid (m.p. 58.2 °C).

**HRMS (ESI):** *m/z* calcd for [C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>5</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 317.1108, found 317.1080

### benzyl cyclopropoxy(4-nitrophenyl)carbamate (19r)




$^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.22 (d,  $J = 9.2$  Hz, 2H), 7.66 (d,  $J = 9.2$  Hz, 2H), 7.45 – 7.35 (m, 5H), 5.31 (s, 2H), 4.07 (tt,  $J = 6.1, 2.9$  Hz, 1H), 0.94 – 0.87 (m, 2H), 0.61 – 0.55 (m, 2H).

$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  153.96, 146.49, 144.32, 135.22, 128.89 (2C), 128.85, 128.55 (2C), 124.53 (2C), 120.21 (2C), 69.02, 59.49, 5.98 (2C).

**Yield:** 283.4 mg, 86%. Yellow solid (m.p. 86.6 °C).

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}_5\text{Na}]^+$  ( $[\text{M}+\text{Na}]^+$ ): 351.0951, found 351.0939

### *tert*-butyl ((2*R*)-2-butylcyclopropoxy)(4-(trifluoromethyl)phenyl)carbamate (19s)



$^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.58 (d,  $J = 8.7$  Hz, 2H), 7.54 (d,  $J = 8.7$  Hz, 2H), 3.71 (dt,  $J = 6.2, 2.3$  Hz, 1H), 1.55 (s, 9H), 1.31 – 1.19 (m, 6H), 1.07 – 0.98 (m, 2H), 0.88 – 0.84 (m, 3H), 0.39 (q,  $J = 6.2$  Hz, 1H).


$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  153.2, 144.4, 126.6 (q,  $J = 32.7$  Hz, 2C), 125.6 (q,  $J = 3.7$  Hz), 124.1 (q,  $J = 271.6$  Hz), 120.9 (2C), 83.0, 64.4, 31.0, 30.8, 28.2 (3C), 22.2,

19.1, 14.0, 12.7.

**Yield:** 50 mg, 45%. Colorless oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{19}\text{H}_{26}\text{F}_3\text{NO}_3\text{Na}]^+$  ( $[\text{M}+\text{Na}]^+$ ): 396.1757; found 396.1736


### Preparation of 2-Hydroxy-tetrahydroquinolines via [3,3]-Rearrangement of *N*-arylated-*O*-cyclopropyl Hydroxamates



*N*-arylated-*O*-cyclopropyl hydroxamate (50 mg, 0.2 mmol, 1.0 equiv) was added to an 8 mL oven-dried vial equipped with a stir bar. The vial was capped, placed under argon atmosphere and trifluoroethanol (2.0 mL, 0.1M) was added. Triethylamine (55.8  $\mu\text{L}$ , 0.4 mmol, 2.0 equiv) was then added to the solution via syringe. The reaction mixture was stirred at rt for 6-24 hours. After complete consumption of the starting material was confirmed via TLC, the reaction mixture was concentrated under reduced pressure. The crude mixture was then purified using flash chromatography (12 % EA in hexanes) on a Biotage Isolera system to give the desired tetrahydroquinoline products.

## Characterization of 2-hydroxy-tetrahydroquinolines


### *tert*-butyl 2-hydroxy-3,4-dihydroquinoline-1(2*H*)-carboxylate (20a)



**Yield:** 276 mg, 60%. Yellow oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>14</sub>H<sub>20</sub>NO<sub>3</sub>]<sup>+</sup> ([M+H]<sup>+</sup>): 250.1438; found 250.1440


### methyl 2-hydroxy-3,4-dihydroquinoline-1(2*H*)-carboxylate (20b)



**Yield:** 65 mg, 46%. Yellow oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>11</sub>H<sub>14</sub>NO<sub>3</sub>]<sup>+</sup> ([M+H]<sup>+</sup>): 208.0968, found 208.0961

### ethyl 2-hydroxy-3,4-dihydroquinoline-1(2*H*)-carboxylate (20c)




**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)** δ 155.69, 136.04, 132.14, 127.39, 126.50, 123.97, 123.85, 79.06, 62.39, 31.05, 24.56, 14.55.

**Yield:** 25.2 mg, 57%. Yellow oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>12</sub>H<sub>15</sub>NO<sub>3</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 244.0944, found 244.0924

**benzyl 2-hydroxy-3,4-dihydroquinoline-1(2H)-carboxylate (20d)**




$^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ )  $\delta$  155.50, 135.94, 135.87, 132.19, 128.80 (2C), 128.52, 128.31(2C), 127.45, 126.61, 124.16, 123.91, 79.29, 68.08, 31.06, 24.57.

**Yield:** 18.6 mg, 53%. Yellow oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{17}\text{H}_{17}\text{NO}_3\text{Na}]^+$  ( $[\text{M}+\text{Na}]^+$ ): 306.1101, found 306.1107


***tert*-butyl 6-bromo-2-hydroxy-3,4-dihydroquinoline-1(2H)-carboxylate (20e)**



**Yield:** 76.8 mg, 52%. Yellow oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{14}\text{H}_{19}\text{BrNO}_3]^+$  ( $[\text{M}+\text{H}]^+$ ): 328.0543; found 328.0534

***tert*-butyl 6-chloro-2-hydroxy-3,4-dihydroquinoline-1(2H)-carboxylate (20f)**




**Yield:** 27 mg, 60%. White solid (m.p. 108.4 °C).

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{14}\text{H}_{18}\text{ClNO}_3\text{Na}]^+$  ( $[\text{M}+\text{Na}]^+$ ): 306.0867, found 306.0857



**benzyl 6-chloro-2-hydroxy-3,4-dihydroquinoline-1(2H)-carboxylate (20g)**




**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)** 155.16, 135.64, 134.57, 133.69, 129.16, 128.89 (2C), 128.69, 128.39 (2C), 127.37, 126.62, 125.00, 79.02, 68.29, 30.61, 24.34.

**Yield:** 15.4 mg, 22%. Colorless oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>17</sub>H<sub>16</sub>ClNO<sub>3</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 340.0711, found 340.0693

***tert*-butyl 6-cyano-2-hydroxy-3,4-dihydroquinoline-1(2H)-carboxylate (20h)**




**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)**: δ 153.8, 140.7, 132.1, 131.2, 130.3, 123.7, 119.0, 106.3, 83.3, 78.6, 29.9, 28.3 (3C), 23.9.

**Yield:** 54 mg, 66%. Colorless oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>15</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub>]<sup>+</sup> ([M+H]<sup>+</sup>): 275.1390; found 275.1379

***tert*-butyl 2-hydroxy-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate (20i)**




**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)**: δ 154.2, 139.6, 131.9, 125.2 (q, *J* = 32.6 Hz), 124.4 (q, *J* = 3.6 Hz), 124.3 (q, *J* = 242.3 Hz), 123.5, 123.3 (q, *J* = 3.7 Hz), 82.9, 78.8, 30.3, 28.4 (3C), 24.3.

**<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>)** –62.03 (s).

**Yield:** 74 mg, 78%. Colorless oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>15</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>3</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 340.1131; found 340.1101

**methyl 2-hydroxy-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate (20j)**



**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)** δ 7.71 (d, *J* = 8.6 Hz, 1H), 7.44 (dd, *J* = 8.6, 2.2 Hz, 1H), 7.38 (s, 1H), 5.88 (t, *J* = 6.0 Hz, 1H), 3.90 (br s, 1H), 3.87 (s, 3H), 2.80 (ddd, *J* = 15.2, 7.7, 4.0 Hz, 1H), 2.60 (ddd, *J* = 14.6, 9.7, 3.8 Hz, 1H), 2.20 (dddd, *J* = 13.3, 7.7, 5.5, 3.9 Hz, 1H), 1.89 (dddd, *J* = 13.6, 10.2, 6.6, 4.0 Hz, 1H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)** δ 155.74, 139.18, 132.03, 125.83 (q, *J* = 32.6 Hz), 124.67 (q, *J* = 3.9 Hz), 124.26 (q, *J* = 271.6 Hz), 123.75 (q, *J* = 3.7 Hz), 123.58, 78.95, 53.55, 30.33,


24.27.

**<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>)** –62.12 (s).

**Yield:** 25.3 mg, 52%. Yellow oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>12</sub>H<sub>12</sub>F<sub>3</sub>NO<sub>3</sub>K]<sup>+</sup> ([M+K]<sup>+</sup>): 314.0401, found 314.0296

**ethyl 2-hydroxy-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate (20k)**



**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)** δ 7.73 (d, *J* = 8.6 Hz, 1H), 7.44 (dd, *J* = 8.7, 2.2 Hz, 1H), 7.38 (s, 1H), 5.88 (ddd, *J* = 6.5, 5.4, 3.4 Hz, 1H), 4.40 – 4.28 (m, 2H), 3.89 (br s, 1H), 2.80 (ddd, *J* = 15.1, 7.6, 3.9 Hz, 1H), 2.61 (ddd, *J* = 14.6, 9.8, 3.8 Hz, 1H), 2.20 (dddd, *J* = 13.2, 7.6, 5.5, 3.8 Hz, 1H), 1.93 – 1.84 (m, 1H), 1.37 (t, *J* = 7.1 Hz, 3H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)** δ 155.30, 139.30, 132.01, 125.69 (q, *J* = 32.6 Hz), 124.64 (q, *J* = 3.8 Hz), 124.30 (q, *J* = 271.6 Hz), 123.57, 123.70 (q, *J* = 3.7 Hz), 78.92, 62.89,


30.33, 24.32, 14.57.

**<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>)** –62.09 (s).

**Yield:** 20.0 mg, 51%. Yellow oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>13</sub>H<sub>14</sub>F<sub>3</sub>NO<sub>3</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 312.0818, found 312.0808

**benzyl 2-hydroxy-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate (20l)**



**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)** δ 7.74 (d, *J* = 8.6 Hz, 1H), 7.51 – 7.33 (m, 7H), 5.91 (td, *J* = 6.0, 3.4 Hz, 1H), 5.34 (d, *J* = 12.2 Hz, 1H), 5.28 (d, *J* = 12.2 Hz, 1H), 3.85 (br s, 1H), 2.80 (ddd, *J* = 15.2, 7.8, 3.9 Hz, 1H), 2.61 (ddd, *J* = 14.6, 9.7, 3.8 Hz, 1H), 2.19 (dp, *J* = 13.2, 4.3 Hz, 1H), 1.89 (dddd, *J* = 13.6, 10.0, 6.5, 3.9 Hz, 1H).


**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)** δ 155.06, 139.15, 135.46, 132.00, 128.93 (2C), 128.79, 128.48 (2C), 125.81 (q, *J* = 32.6 Hz), 124.68 (q, *J* = 3.8 Hz), 124.27 (q, *J* = 271.7 Hz), 123.72 (q, *J* = 3.8 Hz), 123.61, 78.95, 68.50, 30.29, 24.22.

**<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>)** –62.10 (s).

**Yield:** 69.2 mg, 65%. Yellow oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>18</sub>H<sub>16</sub>F<sub>3</sub>NO<sub>3</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 374.0974, found 374.0969

***tert*-butyl 2-hydroxy-5,7-bis(trifluoromethyl)-3,4-dihydroquinoline-1(2*H*)-carboxylate (20m)**



**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):** δ 7.96 (s, 1H), 7.60 (s, 1H), 5.85 (td, *J* = 6.8, 3.4 Hz, 1H), 3.96 (s, 1H), 3.03 (d, *J* = 15.5 Hz, 1H), 2.61 (t, *J* = 12.7 Hz, 1H), 2.28 (dtd, *J* = 13.0, 6.3, 3.6 Hz, 1H), 1.79 (dddd, *J* = 14.0, 11.0, 7.3, 3.3 Hz, 1H), 1.55 (s, 9H);


**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):** δ 153.9, 138.6, 135.2, 128.37 (p, *J* = 32.1, 30.8 Hz), 126.15 (d, *J* = 7.0 Hz), 124.74 (q, *J* = 3.9 Hz), 124.33 (d, *J* = 5.4 Hz), 122.52 (d, *J* = 3.7 Hz), 117.68 – 117.41 (m), 83.5, 78.4, 30.1, 28.2 (3C), 20.8.

**<sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>)** –60.39 (s), –62.96 (s).

**Yield:** 60 mg, 52%. Colorless oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>16</sub>H<sub>18</sub>F<sub>6</sub>NO<sub>3</sub>]<sup>+</sup> ([M+H]<sup>+</sup>): 386.1185; found 386.1190

***tert*-butyl 7-acetyl-2-hydroxy-3,4-dihydroquinoline-1(2*H*)-carboxylate (20n)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):** δ 7.76 (d, *J* = 8.5 Hz, 1H), 7.72 (s, 1H), 7.65 (d, *J* = 8.6 Hz, 1H), 5.81 (q, *J* = 6.1 Hz, 1H), 4.00 – 3.96 (m, 1H), 2.79 (ddd, *J* = 14.5, 7.2, 3.6 Hz, 1H), 2.61 (ddd, *J* = 14.3, 10.2, 3.2 Hz, 1H), 2.56 (s, 3H), 2.17 (dt, *J* = 12.4, 6.2 Hz, 1H), 1.87 (dtt, *J* = 13.5, 6.9, 3.9 Hz, 1H), 1.56 (s, 9H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):** δ 197.2, 154.1, 140.9, 132.1, 131.3, 127.6, 126.8, 123.0, 82.9, 78.8, 30.3, 28.3 (3C), 26.4, 24.3.

**Yield:** 58 mg, 67%. Colorless oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>16</sub>H<sub>22</sub>NO<sub>4</sub>]<sup>+</sup> ([M+H]<sup>+</sup>): 292.1543; found 292.1542

**1-(*tert*-butyl) 6-methyl 2-hydroxy-3,4-dihydroquinoline-1,6(2*H*)-dicarboxylate (20o)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):** δ 7.83 (d, *J* = 10.3 Hz, 1H), 7.79 (s, 1H), 7.62 (d, *J* = 8.6 Hz, 1H), 5.80 (td, *J* = 6.3, 3.4 Hz, 1H), 3.98 (s, 1H), 3.89 (s, 3H), 2.77 (ddd, *J* = 14.8, 7.3, 3.8 Hz, 1H), 2.59 (ddd, *J* = 14.4, 10.1, 3.4 Hz, 1H), 2.17 (dq, *J* = 13.0, 7.5, 5.5 Hz, 1H), 1.85 (dddd, *J* = 13.6, 10.3, 6.8, 3.8 Hz, 1H), 1.56 (s, 9H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):** δ 166.8, 154.2, 140.7, 131.3, 128.8, 127.8, 124.7, 123.1, 82.8, 78.9, 51.9, 30.3, 28.3 (3C), 24.2.

**Yield:** 63 mg, 68%. Colorless oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>16</sub>H<sub>22</sub>NO<sub>5</sub>]<sup>+</sup> ([M+H]<sup>+</sup>): 308.1492; found 308.1480

**dimethyl 2-hydroxy-3,4-dihydroquinoline-1,6(2H)-dicarboxylate (20p)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)** δ 7.84 (d, *J* = 8.6 Hz, 1H), 7.80 (s, 1H), 7.66 (d, *J* = 8.6 Hz, 1H), 5.87 (td, *J* = 6.1, 3.0 Hz, 1H), 3.97 (br s, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 2.79 (ddd, *J* = 15.1, 7.7, 4.0 Hz, 1H), 2.59 (ddd, *J* = 14.5, 9.7, 3.8 Hz, 1H), 2.18 (dddd, *J* = 13.3, 7.7, 5.4, 3.8 Hz, 1H), 1.90 – 1.83 (m, 1H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)** δ 166.87, 155.79, 140.33, 131.42, 129.08, 128.24, 125.37, 123.11, 79.12, 53.53, 52.14, 30.36, 24.20.

**Yield:** 35 mg, 45%. Yellow oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>13</sub>H<sub>15</sub>NO<sub>5</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 288.0842, found 288.0838

***tert*-butyl 2-hydroxy-7-methyl-3,4-dihydroquinoline-1(2H)-carboxylate (20q)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)**: δ 7.37 (s, 1H), 6.98 (d, *J* = 7.6 Hz, 1H), 6.81 (d, *J* = 7.6 Hz, 1H), 5.78 (td, *J* = 7.2, 3.2 Hz, 1H), 3.88 (s, 1H), 2.63 (ddd, *J* = 14.7, 6.4, 3.9 Hz, 1H), 2.50 (ddd, *J* = 14.6, 11.0, 3.4 Hz, 1H), 2.31 (s, 3H), 2.22 (dtd, *J* = 12.7, 6.2, 3.7 Hz, 1H), 1.81 – 1.72 (m, 1H), 1.56 (s, 9H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)**: δ 154.6, 136.1, 135.8, 128.9, 126.9, 124.4, 124.2, 81.9, 78.9, 31.1, 28.4 (3C), 24.1, 21.3.

**Yield:** 16 mg, 20%. Colorless oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>13</sub>H<sub>22</sub>NO<sub>3</sub>]<sup>+</sup> ([M+H]<sup>+</sup>): 264.1594; found 264.1577

***tert*-butyl 2-hydroxy-5-methyl-3,4-dihydroquinoline-1(2H)-carboxylate (20r)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)**: δ 7.33 (d, *J* = 8.2 Hz, 1H), 7.06 (t, *J* = 7.9 Hz, 1H), 6.89 (d, *J* = 7.5 Hz, 1H), 5.83 (td, *J* = 7.0, 3.2 Hz, 1H), 3.74 (s, 1H), 2.74 (ddd, *J* = 15.3, 6.6, 4.2 Hz, 1H), 2.40 (ddd, *J* = 14.9, 10.6, 3.8 Hz, 1H), 2.28 (s, 3H), 2.24 (dtd, *J* = 13.0, 6.2, 4.1 Hz, 1H), 1.76 (dddd, *J* = 13.4, 11.0, 7.2, 4.1 Hz, 1H), 1.54 (s, 9H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)**: δ 154.7, 136.1, 134.5, 130.6, 125.4, 125.3, 122.1, 81.9, 78.5, 30.6, 28.4 (3C), 20.5, 19.6.

**Yield:** 18 mg, 22%. Colorless oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>15</sub>H<sub>21</sub>NO<sub>3</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 286.1414; found 286.1418

***tert*-butyl 2-hydroxy-6-methyl-3,4-dihydroquinoline-1(2H)-carboxylate (20s)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)**: δ 7.40 (d, *J* = 8.3 Hz, 1H), 6.97 (d, *J* = 8.3 Hz, 1H), 6.91 (s, 1H), 5.78 (td, *J* = 7.2, 3.3 Hz, 1H), 3.90 (s, 1H), 2.62 (ddd, *J* = 14.7, 6.3, 3.9 Hz, 1H), 2.51 (ddd, *J* = 14.6, 11.1, 3.4 Hz, 1H), 2.29 (s, 3H), 2.26 – 2.18 (m, 1H), 1.77 (dddd, *J* = 13.3, 11.1, 7.3, 3.8 Hz, 1H), 1.55 (s, 9H).

$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  154.7, 133.8, 133.0, 131.8, 127.8, 126.8, 123.6, 81.9, 79.0, 31.1, 28.4 (3C), 24.6, 20.7.

**Yield:** 30 mg, 38%. Colorless oil.

**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{15}\text{H}_{21}\text{NO}_3\text{Na}]^+$  ( $[\text{M}+\text{Na}]^+$ ): 286.1414, found 286.1404


#### benzyl 2-hydroxy-5-methyl-3,4-dihydroquinoline-1(2H)-carboxylate (20t)



**Yield:** 37 mg, 41%. Colorless oil.


**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{18}\text{H}_{19}\text{NO}_3\text{Na}]^+$  ( $[\text{M}+\text{Na}]^+$ ): 320.1257; found 320.1243

#### Preparation of Derivatized 2-hydroxy-tetrahydroquinoline Products



*Tert*-butyl 2-hydroxy-3,4-dihydroquinoline-1(2H)-carboxylate **20a** (50 mg, 0.2 mmol, 1.0 equiv) was dissolved in EtOH (1 mL, 0.2 M). At room temperature, 2M HCl in Et<sub>2</sub>O (200  $\mu\text{L}$ , 0.4 mmol, 2.0 equiv) was added in two equal portions (100  $\mu\text{L}$  each). The reaction was left stirring at rt for 1 h. Upon reaction completion the mixture was quenched with aq.  $\text{NaHCO}_3$  (2 mL). The organic layer was separated, washed with brine, dried over  $\text{MgSO}_4$  and concentrated. The crude residue was purified using flash chromatography (20% EA in hexanes) on a Biotage Isolera system to give the corresponding *tert*-butyl 2-ethoxy-3,4-dihydroquinoline-1(2H)-carboxylate **21** as a colorless liquid.

***tert*-butyl 2-ethoxy-3,4-dihydroquinoline-1(2*H*)-carboxylate (21)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)** δ 7.54 (d, *J* = 8.2 Hz, 1H), 7.14 (t, *J* = 7.7 Hz, 1H), 7.09 (d, *J* = 7.5 Hz, 1H), 7.01 (t, *J* = 7.4 Hz, 1H), 5.83 (t, *J* = 4.1 Hz, 1H), 3.64 – 3.52 (m, 2H), 2.87 (ddd, *J* = 16.3, 9.7, 6.7 Hz, 1H), 2.66 (dt, *J* = 16.2, 6.0 Hz, 1H), 2.14 (tdd, *J* = 9.7, 6.7, 4.9 Hz, 1H), 1.99 (dddd, *J* = 13.5, 6.8, 5.3, 3.8 Hz, 1H), 1.53 (s, 9H), 1.12 (t, *J* = 7.0 Hz, 3H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)** δ 153.81, 136.12, 130.28, 128.28, 125.81, 125.06, 123.92, 81.41, 81.26, 62.79, 29.25, 28.48 (3C), 23.37, 15.15.


**Yield:** 33.2 mg, 60%. Colorless liquid.

**HRMS (ESI):** *m/z* calcd for [C<sub>16</sub>H<sub>23</sub>NO<sub>3</sub>Na]<sup>+</sup> ([M+Na]<sup>+</sup>): 300.1570, found 300.1568



*Tert*-butyl 2-hydroxy-3,4-dihydroquinoline-1(2*H*)-carboxylate **20a** (50 mg, 0.2 mmol, 1.0 equiv) was dissolved in DCM (2 mL, 0.1 M). To this solution at rt was added Cu(OAc)<sub>2</sub> (36 mg, 0.2 mmol, 1.0 equiv), Et<sub>3</sub>N (101 mg, 1 mmol, 5.0 equiv), Na<sub>2</sub>SO<sub>4</sub> (142 mg, 1 mmol, 5.0 equiv) and phenylboronic acid (49 mg, 0.4 mmol, 2.0 equiv), in that order. The mixture was stirred at rt for 24 hours.<sup>[5]</sup> Upon reaction completion, the mixture was then passed through a pad of celite and washed three times with DCM (5 mL). The combined organic washes were concentrated, and the crude residue was purified using flash chromatography (20-30% EA in hexanes) on a Biotage Isolera system to give the corresponding *tert*-butyl 2-phenoxy-3,4-dihydroquinoline-1(2*H*)-carboxylate **22** as a colorless oil.

***tert*-butyl 2-phenoxy-3,4-dihydroquinoline-1(2*H*)-carboxylate (22)**




**<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)** δ 7.56 (d, *J* = 7.8 Hz, 1H), 7.26 (t, *J* = 7.9 Hz, 2H), 7.14 (t, *J* = 7.8 Hz, 2H), 7.04 (t, *J* = 7.4 Hz, 1H), 6.99 (dd, *J* = 14.0, 7.6 Hz, 3H), 6.52 (t, *J* = 3.7 Hz, 1H), 3.05 (dt, *J* = 16.5, 8.5 Hz, 1H), 2.79 (dt, *J* = 16.2, 5.6 Hz, 1H), 2.26 (dq, *J* = 9.4, 4.2 Hz, 2H), 1.42 (s, 9H).

**<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)** δ 56.6, 152.8, 135.7, 129.5, 129.3, 128.2, 125.9, 124.7, 123.9, 122.1, 117.7, 81.6, 81.2, 28.5, 28.1, 23.0.


**Yield:** 98 mg, 39%. Colorless oil.

**HRMS (ESI):** *m/z* calcd for [C<sub>20</sub>H<sub>24</sub>NO<sub>3</sub>]<sup>+</sup> ([M+H]<sup>+</sup>): 326.1751; found 326.1742



*Tert*-butyl 2-hydroxy-3,4-dihydroquinoline-1(2H)-carboxylate **20a** (50 mg, 0.2 mmol, 1.0 equiv) was dissolved in DCM (2 mL, 0.1 M). Then allyltrimethylsilane (39 mg, 0.34 mmol, 1.7 equiv) was added. The solution was cooled to  $0\text{ }^\circ\text{C}$  and  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  (48 mg, 0.34 mmol, 1.7 equiv) was added to the solution dropwise. After stirring for 8 hours at  $0\text{ }^\circ\text{C}$ , the reaction was removed from the ice bath and allowed to warm to rt.<sup>[6]</sup> The mixture was concentrated to give the corresponding *tert*-butyl 2-(allyloxy)-3,4-dihydroquinoline-1(2H)-carboxylate **23** as a pure colorless oil.


#### *tert*-butyl 2-(allyloxy)-3,4-dihydroquinoline-1(2H)-carboxylate (**23**)



<sup>13</sup>C NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  144.5, 134.9, 129.2, 126.7, 121.2, 117.9, 117.0, 114.0, 50.5, 41.1, 28.2, 26.4.

**Yield:** 33 mg, 63%. Colorless oil.


**HRMS (ESI):**  $m/z$  calcd for  $[\text{C}_{12}\text{H}_{16}\text{N}]^+$  ( $[\text{M}+\text{H}]^+$ ): 174.1277; found 174.1289



Methyl 2-(dimethoxyphosphoryl)acetate (109 mg, 0.6 mmol, 2.0 equiv) was dissolved in THF (2 mL) and cooled to  $0\text{ }^\circ\text{C}$ . NaH (0.6 mmol, 2.0 equiv) was slowly added to the solution. Then a *tert*-butyl 2-hydroxy-3,4-dihydroquinoline-1(2H)-carboxylate **20a** (75 mg, 0.3 mmol, 1.0 equiv) solution in THF (1.0 mL, 0.3 M), was added dropwise. The reaction was allowed to warm to room temperature and stirred overnight. Upon reaction completion, water was added to quench the reaction. The aqueous layer was extracted with DCM (3 x 5 mL). The combined organic layers were dried over anhydrous sodium sulfate and

concentrated.<sup>[7]</sup> The crude mixture was purified using flash chromatography (10-20% EA in hexanes) on a Biotage Isolera system to give the corresponding *tert*-butyl 2-(2-oxopropoxy)-3,4-dihydroquinoline-1(2*H*)-carboxylate **24** as a colorless oil.

***tert*-butyl 2-(2-oxopropoxy)-3,4-dihydroquinoline-1(2*H*)-carboxylate (24)**



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 7.49 (d, *J* = 8.2 Hz, 1H), 7.19 – 7.11 (m, 1H), 7.07 (d, *J* = 5.9 Hz, 1H), 7.01 (t, *J* = 7.4 Hz, 1H), 4.93 – 4.82 (m, 1H), 3.64 (s, 3H), 2.70 – 2.61 (m, 3H), 2.38 (dd, *J* = 14.6, 8.0 Hz, 1H), 2.30 (dt, *J* = 13.1, 6.6 Hz, 1H), 1.65 (dq, *J* = 13.4, 6.7 Hz, 1H), 1.50 (s, 9H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 171.5, 153.5, 136.7, 131.3, 127.7, 125.9, 125.6, 123.9, 80.9, 51.6, 50.1, 38.5, 29.1, 28.3, 24.9.

**Yield:** 63 mg, 69%. Colorless oil.

**HRMS (ESI-TOF):** calc'd for C<sub>17</sub>H<sub>24</sub>NO<sub>4</sub> [M+H]<sup>+</sup> 306.1700; found 306.1704.

## References

- [1] A. J. Pearce, D. S. Walter, C. S. Frampton, T. Gallagher, *J. Chem. Soc., Perkin Trans. 1* **1998**, 847-852.
- [2] A. S. Patil, D. L. Mo, H. Y. Wang, D. S. Mueller, L. L. Anderson, *Angew. Chem. Int. Ed.* **2012**, *51*, 7799-7803.
- [3] L. Steemers, L. Wijsman, J. H. van Maarseveen, *Adv. Synth. Catal.* **2018**, *360*, 4241-4245.
- [4] J. C. Lorenz, J. Long, Z. Yang, S. Xue, Y. Xie, Y. Shi, *J. Org. Chem.* **2004**, *69*, 327-334.
- [5] D. G. Hall, in *Boronic acids : preparation and applications in organic synthesis, medicine and materials*, Second ed., Wiley-VCH, Weinheim, **2011**.
- [6] H. Sakurai, *Pure & Appl. Chem.* **1982**, *54*, 1-22.
- [7] J. D. Scott, M. W. Miller, S. W. Li, S. I. Lin, H. A. Vaccaro, L. W. Hong, D. E. Mullins, M. Guzzi, J. Weinstein, R. A. Hodgson, G. B. Varty, A. W. Stamford, T. Y. Chan, B. A. McKittrick, W. J. Greenlee, T. Priestley, E. M. Parker, *Bioorg. Med. Chem. Lett.* **2009**, *19*, 6018-6022.




# NMR Spectra of Reported Compounds

7.85  
7.85  
7.84  
7.84  
7.76  
7.75  
7.75  
7.75  
7.75  
7.75  
CDCl<sub>3</sub>

4.41  
4.41  
4.41  
4.40  
4.40  
4.40  
4.39  
4.39  
4.39  
4.39


1.18  
1.18  
1.17  
1.17  
1.17  
1.17  
1.16  
1.16  
1.16  
1.16  
1.15  
1.15  
1.15


0.69  
0.69  
0.68  
0.68  
0.68  
0.67  
0.67  
0.67





**16a**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)

















7.85  
7.85  
7.84  
7.84  
7.83  
7.83  
7.82  
7.82  
7.76  
7.76  
7.75  
7.75  
7.75  
7.74  
7.73  
7.73  
7.26 CDCl<sub>3</sub>



**16d**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)








7.76  
7.75  
7.75  
7.73  
7.73  
7.72  
7.72  
7.71  
7.70  
7.69  
7.69  
7.68  
7.68  
7.67  
7.58  
7.57  
7.57  
7.56  
7.35  
7.34  
7.34  
7.33  
7.32  
7.32  
7.31  
7.26 CDCl3




**16e**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)

1.84  
1.83  
1.82  
1.82  
1.13  
1.12  
1.12  
1.11






7.86  
7.85  
7.85  
7.84  
7.84  
7.83  
7.83  
7.82  
7.77  
7.76  
7.76  
7.75  
7.75  
7.74  
7.74  
7.73  
7.26 CDCl<sub>3</sub>





**16f**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)


1.73  
1.72  
1.71  
1.71  
1.70  
1.70  
1.69  
1.69  
1.68  
1.67  
1.55  
1.54  
1.53  
1.52  
1.05  
1.03  
0.20  
0.19  
0.19  
0.18














**17a**

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 600 MHz)







<sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 151 MHz)











**17b**


<sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz)






**18a**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)









**18a**


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)













**18c**

<sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz)









**18d**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)








**18d**


<sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz)














**19a**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)









**19b**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)





7.43  
7.41  
7.37  
7.35  
7.34  
7.26 CDCl<sub>3</sub>  
7.21  
7.20  
7.19





**19c**

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)

4.30  
4.28  
4.27  
4.26  
4.03  
4.03  
4.02  
4.02  
4.01


1.34  
1.33  
1.32  
0.88  
0.88  
0.87  
0.87  
0.86  
0.86  
0.86  
0.85  
0.85  
0.56  
0.55  
0.55  
0.54  
0.54  
0.53







**19c**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)









**19d**


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)






**19e**


$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 600 MHz)






**19e**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)



7.36  
7.35  
7.35  
7.34  
7.34  
7.33  
7.33  
7.30  
7.30  
7.29  
7.29  
7.28  
7.28  
7.26 CDCl<sub>3</sub>





**19f**

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)

3.99  
3.98  
3.98


1.52  
0.86  
0.86  
0.86  
0.85  
0.85  
0.85  
0.85  
0.84  
0.55  
0.55  
0.54  
0.54  
0.53  
0.53







7.40  
7.39  
7.38  
7.38  
7.37  
7.37  
7.37  
7.36  
7.35  
7.33  
7.32  
7.32  
7.31  
7.31  
7.26 CDCl<sub>3</sub>



**19g**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)


—5.26

4.02  
4.02  
4.01  
4.01  
4.00

0.85  
0.85  
0.84  
0.84  
0.84  
0.83  
0.83  
0.83  
0.82  
0.82


0.54  
0.54  
0.54  
0.53  
0.53






**19g**


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)







**19h**

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)












**19i**

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)








**19i**

<sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz)


- B (q)  
125.58  
J(3.7)
- A (q)  
126.62  
J(32.7)
- C (q)  
124.11  
J(271.6)


























**19m**  
 $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 600 MHz)










**19n**

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)











**19o**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)






**19o**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)




8.03  
8.03  
8.02  
8.01  
8.00  
8.00  
7.98  
7.53  
7.52  
7.51  
7.26 CDCl<sub>3</sub>




**19p**

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)


4.06  
4.06  
4.05  
4.04  
4.04  
4.03  
4.03  
4.02  
3.89  
3.89  
3.85  
3.85  
3.84  
3.83  
0.89  
0.89  
0.89  
0.88  
0.88  
0.87  
0.87  
0.86  
0.86  
0.86  
0.57  
0.56  
0.56  
0.55  
0.55  
0.54  
0.54  
0.53  
0.53









**19p**

<sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz)













**19r**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)




















**20a**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)










**20b**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)










**20c**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)












**20d**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)












**20e**


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)


















**20h**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)






**20h**


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)







**20i**

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)










**20i**


<sup>19</sup>F NMR (CDCl<sub>3</sub>, 471 MHz)

-62.03











**20j**


**<sup>19</sup>F NMR (CDCl<sub>3</sub>, 471 MHz)**

—-62.12











**20k**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)








**20k**


**<sup>19</sup>F NMR (CDCl<sub>3</sub>, 471 MHz)**

---62.09











**201**

<sup>19</sup>F NMR (CDCl<sub>3</sub>, 471 MHz)


—62.10







**20m**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 600 MHz)











**20m**

**<sup>19</sup>F NMR (CDCl<sub>3</sub>, 471 MHz)**


-60.39  
-62.96







**20n**

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)









**20o**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)








**20o**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)









**20p**


<sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz)






**20q**

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)









**20q**


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)






**20r**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)






**20r**


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)






**20s**


$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 600 MHz)






**20s**


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)






**20t**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)







**20t**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)











**21**


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)






**22**


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)






**22**


<sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz)






**23**


$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 600 MHz)






**23**


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)






**24**

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 600 MHz)





**24**

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 151 MHz)

